GlassScriptPhysician profile
Mitul Vinodkumar Mehta
NPI 1801279617
$3,488.72
in general payments reported to CMS, 2019-2025
27 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $396 · 2021: $648 · 2022: $214 · 2023: $336 · 2024: $901 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $428.17 | 2022-2024 | Interstim |
| Astrazeneca Pharmaceuticals LP | $359.26 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Silk Road Medical, INC. | $357.92 | 2020-2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Glaxosmithkline, LLC. | $356.49 | 2019-2025 | Trelegy Ellipta |
| Abbvie INC. | $246.60 | 2021-2025 | |
| Novo Nordisk INC | $246.07 | 2019-2025 | Wegovy, Rybelsus |
| Pfizer INC. | $175.99 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $133.19 | 2019-2021 | |
| Abbott Laboratories | $132.63 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $125.00 | 2020 | |
| Boston Scientific Corporation | $124.10 | 2024 | |
| Kestra Medical Technology Services, INC. | $123.11 | 2024 | Assure Wcd |
| Merit Medical Systems INC | $112.66 | 2025 | Esophyx |
| Merck Sharp & Dohme LLC | $95.98 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Lilly USA, LLC | $74.24 | 2023-2025 | Mounjaro, Zepbound |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $69.59 | 2024-2025 | Repatha, Otezla, Otezla |
| Enterra Medical, INC. | $51.77 | 2025 | |
| Nestle Healthcare Nutrition INC. | $49.70 | 2021 | |
| Astellas Pharma US INC | $49.53 | 2024 | Veozah |
| Exact Sciences Corporation | $40.59 | 2024 | Cologuard Collection Kit |
| Cranial Technologies, INC | $31.16 | 2021 | |
| Gilead Sciences, INC. | $21.13 | 2021 | |
| Vanda Pharmaceuticals INC. | $19.48 | 2021 | |
| Mylan Specialty L.P. | $18.86 | 2024 | Yupelri |
| Covidien LP | $16.26 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.01 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitul Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.